Specialized Disclosure Report (sd)
May 23 2019 - 11:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
MERIDIAN BIOSCIENCE, INC.
(Exact name of the registrant as specified in its charter)
Ohio
|
0-14902
|
31-0888197
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
3471 River Hills Drive,
Cincinnati, Ohio
|
|
45244
|
(Address of principal executive offices)
|
|
(Zip code)
|
|
|
|
|
|
|
|
Eric S. Rasmussen
(513) 271-3700
|
|
|
(Name and telephone number, including area code,
of the person to contact in connection with this report.)
|
|
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and
provide the period to which the information in this form applies:
X
Rule
13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2018.
___ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal
year ended ___________________.
SECTION 1. CONFLICT MINERALS DISCLOSURE
Item 1.01
Conflict Minerals Disclosure and Report
Meridian Bioscience, Inc. ("Meridian" or the "Company") evaluated its products during the year ended
December 31, 2018 and determined that certain products manufactured or contracted to be manufactured by the Company contain tin, tungsten, tantalum, and/or gold. As a result, Meridian has filed a Conflict Minerals Report ("CMR"). A copy of
Meridian's CMR is furnished as Exhibit 1.01 to this Form SD and is incorporated herein by reference. Copies of Meridian's Form SD and CMR are also available at the Meridian corporate website:
www.meridianbioscience.com
.
SECTION 2. EXHIBITS
Item 2.01
Exhibits
Exhibit 1.01
Conflict Minerals Report as required by Items 1.01 and 1.02 of this
Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the duly authorized undersigned.
Date: May 23, 2019
|
MERIDIAN BIOSCIENCE, INC.
By:
/s/ Eric S. Rasmussen
Eric S. Rasmussen
Executive Vice President and Chief Financial Officer
|
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024